532 related articles for article (PubMed ID: 26310908)
1. Strategies for combining immunotherapy with radiation for anticancer therapy.
Seyedin SN; Schoenhals JE; Lee DA; Cortez MA; Wang X; Niknam S; Tang C; Hong DS; Naing A; Sharma P; Allison JP; Chang JY; Gomez DR; Heymach JV; Komaki RU; Cooper LJ; Welsh JW
Immunotherapy; 2015; 7(9):967-980. PubMed ID: 26310908
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
3. Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.
Huang MA; Krishnadas DK; Lucas KG
J Immunol Res; 2015; 2015():675269. PubMed ID: 26587548
[TBL] [Abstract][Full Text] [Related]
4. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
Baxevanis CN; Papamichail M
Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086
[TBL] [Abstract][Full Text] [Related]
5. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
6. Challenges of cancer therapy with natural killer cells.
Klingemann H
Cytotherapy; 2015 Mar; 17(3):245-9. PubMed ID: 25533934
[TBL] [Abstract][Full Text] [Related]
7. Novel immunotherapies for hematologic malignancies.
Nelson MH; Paulos CM
Immunol Rev; 2015 Jan; 263(1):90-105. PubMed ID: 25510273
[TBL] [Abstract][Full Text] [Related]
8. Update on the current revolution in cancer immunotherapy.
Renrick AN; Dunbar ZT; Shanker A
Immunotherapy; 2019 Jan; 11(1):15-20. PubMed ID: 30702010
[No Abstract] [Full Text] [Related]
9. A new therapeutic potential for cancers: One CAR with 2 different engines!
Sheikhi A; Jafarzadeh A
Hum Vaccin Immunother; 2017 Aug; 13(8):1786-1788. PubMed ID: 28494200
[TBL] [Abstract][Full Text] [Related]
10. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
11. [Immune-checkpoints: the new anti-cancer immunotherapies].
Ileana E; Champiat S; Soria JC
Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
[TBL] [Abstract][Full Text] [Related]
12. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
Yaguchi T; Kawakami Y
Int Immunol; 2016 Aug; 28(8):393-9. PubMed ID: 27401477
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more.
Chiossone L; Vienne M; Kerdiles YM; Vivier E
Semin Immunol; 2017 Jun; 31():55-63. PubMed ID: 28943093
[TBL] [Abstract][Full Text] [Related]
14. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
Renner C; Pfreundschuh M
J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
[TBL] [Abstract][Full Text] [Related]
15. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
16. [Breaking immune tolerance in cancer].
Desbois M; Champiat S; Chaput N
Bull Cancer; 2015 Jan; 102(1):34-52. PubMed ID: 25609492
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
18. Adoptive cell therapy: past, present and future.
Cohen JE; Merims S; Frank S; Engelstein R; Peretz T; Lotem M
Immunotherapy; 2017 Jan; 9(2):183-196. PubMed ID: 28128715
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint combinations from mouse to man.
Ai M; Curran MA
Cancer Immunol Immunother; 2015 Jul; 64(7):885-92. PubMed ID: 25555570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
